Galena implodes as trial monitors call a halt to a failed PhIII cancer study
Shares of Galena ($GALE) were eviscerated this morning, dropping 78% after the biotech announced that it had stopped a Phase III study of its lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
